

PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet 1 of

Application Number	10/770,654
Filing Date	02-03-2004
First Named Inventor	HEINELT
Group Art Unit	1626
Examiner Name	Stockton
Attorney Docket Number	DEAV2003/0007 - US - NP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Type of Document
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
[Handwritten marks]		JP	02306916		TAKAO, et al.	12-20-1990		
		JP	10330369		TERUHISA, et al.	12-15-1998		
		WO	WO01/21160		ULLRICH, et al.	03-29-2001		
		WO	WO90/14338		BANTICK, et al.	11-29-1990		
		WO	WO01/21582		DORSCH, et al.	03-29-2001		
		WO	WO01/72742		GERICKE, et al.	10-04-2001		
		WO	WO01/79186		GERICKE, et al.	10-25-2001		
		WO	WO02/20496		GERICKE, et al.	03-14-2002		
		GB	1,131,191		GRUENFELD	10-23-1968		

**Examiner
Signature**

Lam J. Stelling

Date _____

Considered


i / 17 / 07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐



PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/770,654		
		Filing Date	02-03-2004		
		First Named Inventor	HEINELT		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	DEAV2003/0007 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AKHTER, et al., Squalamine, a Novel Cationic Steroid, Specifically Inhibits the Brush-border Na ⁺ /H ⁺ Exchanger Isoform NHE3, The American Physiological Society, 1999, c136-c144	
		ERNSBERGER, et al., Clonidine Binds To Imidazole Binding Sites As Well As Alpha2-Adrenoceptors In The Ventrolateral Medulla, European Journal of Pharmacology, 134 (1987) 1-13	
		FLIEGEL, et al., Regulation And Characterization Of The Na ⁺ /H ⁺ Exchanger, Biochem. Cell. Biol., 76: (1998), 735-741	
		JACOBSON, et al., Chem. Ber. (1908), 41, 524	
		JANSSENS, et al., New Antihistaminic N-Heterocyclic 4-Piperidinamines. 1. Synthesis and Antihistaminic Activity of N-(4-Piperidinyl)-1H-Benzimidazol-2-Amines, J. Med. Chem. (1985), 28, 1925-1933	
		JEN, et al., Amidines and Related Compounds. 6. Studies on Structure-Activity Relationships of Antihypertensive and Antisecretory Agents Related to Clonidine, Journal of Medicinal Chemistry, 1975, Vol. 18, No. 1., 90-99	
		MA, et al., Expression And Localization Of Na ⁺ /H ⁺ Exchangers In Rat Central Nervous System, Neuroscience, (1997), Vol. 79. No. 2. pp. 591-603.	
		MOHSEN, et al., The Cyclodesulfurization Of Thio Compounds; VII. A New Facile Synthesis Of Na-Substituted Benzimidazoles, Communication, January 1974, S. 41-42	
		ORLOWSKI, et al., Molecular Cloning Of Putative Members Of The Na/H Exchanger, J. Biological Chemistry, 1992, vol. 267, 9331-9339	
		RASTOGI, et al., 2-Aminobenzimidazoles In Organic Syntheses, Synthesis, (1983), 861-882	

Examiner Signature		Date Considered	1/17/07
-----------------------	--	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) in -ide this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/770,654
Filing Date	02-03-2004
First Named Inventor	HEINELT
Group Art Unit	
Examiner Name	
Attorney Docket Number	DEAV2003/0007 - US - NP

Sheet

3

of

3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TUNCBILEK, et al., Synthesis And Antimicrobial Activity Of Some New Anilino Benzimidazoles, Arch. Pharm. Pharm. Med. Chem., (1997), 330 (12), 372-376	
		WU, et al., 1-Cyanoimidazole As A Mild And Efficient Electrophilic Cyanating Agent, Organic Letters, 2000, Vol. 2, No. 6, 795-797	

Examiner Signature		Date Considered	1/17/07
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.